Ascendis Pharma A/S ((ASND)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ascendis Pharma A/S recently updated its clinical study titled BelieveIT-201: Phase 2, Randomized Open-labeled Trial of TransCon (TC) TLR7/8 Agonist in Combination With Pembrolizumab or With TC IL-2 β/γ, or Pembrolizumab Alone as Neoadjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. The study aimed to evaluate the safety and efficacy of these treatments before surgery in patients with advanced head and neck cancer, potentially improving outcomes and survival rates.
The interventions tested include the TransCon TLR7/8 Agonist, a prodrug designed to activate the immune system, Pembrolizumab, an immunotherapy that blocks the PD-1 pathway, and TransCon IL-2 β/γ, which stimulates the immune system. These are intended to enhance the body’s ability to fight cancer.
The study was designed as a randomized, open-label, Phase 2 trial with a parallel intervention model. It involved no masking and focused on treatment as its primary purpose. Participants were allocated to different treatment arms to compare safety and efficacy.
Key dates for the study include an actual start date of September 29, 2023, and a last update submitted on July 8, 2025. These dates are crucial for tracking the study’s progress and any changes in its status.
The termination of this study could impact Ascendis Pharma’s stock performance and investor sentiment, as it may affect the company’s pipeline and future revenue prospects. Competitors in the oncology space might seize this opportunity to advance their own treatments.
The study has been terminated, and further details can be accessed on the ClinicalTrials portal.